The purpose is to ensure test availability for sars-COV-2 after the emergency authorization closes by submitting an in vitro diagnostic or IVD assay for sars-COV-2, influenza (flu) a, flu B and…
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50122C00074
- Awardee
-
Hologic, Inc. UEI WHWJBKU5SX73
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $22,300,000
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Pre-Solicitation · BAA18100SOL00003 · Posted Oct 16, 2017
- Contract value 57% obligated
-
- $22,300,000.00 Current, with exercised options
- $38,900,000.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $3,300,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $19,000,000 |
About this award
This is a $38,900,000.00 firm fixed-price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Hologic, Inc. to ensure test availability for SARS-CoV-2 after the emergency authorization closes. The purpose is for Hologic to submit an in vitro diagnostic (IVD) assay for SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) by September 30, 2027.
This contract was awarded under a Broad Agency Announcement (BAA) originally issued by BARDA in 2017 to solicit proposals for the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats. The BAA sought proposals focused on areas including vaccines, therapeutics, diagnostics, and other technologies to support BARDA's public health emergency preparedness mission. There was no set-aside designation for this opportunity.
Description
The purpose is to ensure test availability for sars-COV-2 after the emergency authorization closes by submitting an in vitro diagnostic or IVD assay for sars-COV-2, influenza (flu) a, flu B and respiratory syncytial virus (RSV) along with a respirato
Quick answers
Who was awarded contract 75A50122C00074?
75A50122C00074 was awarded to Hologic, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2022.
How much is contract 75A50122C00074 worth?
The government has obligated $22,300,000 on 75A50122C00074. Its potential value, with all options, is $38,900,000.
Was contract 75A50122C00074 competed?
The extent of competition for 75A50122C00074 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award